Dr Kaddoura on Genomic Determinants of Outcomes in IGH/CCND1+ Myeloma Treated With Venetoclax

Marcella Ali Kaddoura, MD, assistant professor, Department of Medicine, the Division of Myeloma, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, discusses an investigation into the genomic determinants of clinical outcomes in patients with t(11;14)-positive multiple myeloma harboring IHG/CCND1 rearrangements who have been treated with venetoclax (Venclexta). These findings were shared by Kaddoura and colleagues at the 2024 ASH Annual Meeting.